Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term **advanced glycation end-product formation intermediates / reactive carbonyl species** refers primarily to highly reactive dicarbonyl compounds such as methylglyoxal, glyoxal, and 3-deoxyglucosone, which are generated during the Maillard reaction as intermediates in the non-enzymatic glycation of proteins, nucleic acids, or lipids[2][3]. These intermediates are not proteins, enzymes, or receptors, but short-lived chemical species whose accumulation leads to the eventual formation of advanced glycation end-products (AGEs)[2][3][5]. Reactive carbonyl species originate from sugar autoxidation, lipid peroxidation, or metabolic pathways (such as glycolysis or the polyol pathway), and are key mediators of "carbonyl stress."[2][3] They covalently modify biological macromolecules, contributing to protein dysfunction, oxidative stress, and inflammation[4]. They are strongly implicated in the pathogenesis of chronic diseases like diabetes, cardiovascular disease, and neurodegeneration due to their damaging effects and their role in AGE formation[1][4]. Pharmacological intervention often focuses on scavenging these intermediates to reduce downstream AGE formation, but targeting them directly is chemically challenging and not equivalent to traditional receptor or enzyme drug targeting[2][3].
Carbonyl scavenging; Prevention of advanced glycation end-product formation
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Advanced glycation end-product formation intermediate.